⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 12, 2025Clinical and Molecular HepatologyOpen Access

Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations

Sherlot Juan Song Eileen L. Yoon Vincent Wai-Sun Wong Ae Jeong Jo Grace Lai-Hung Wong Jimmy Che‐To Lai Dae Won Jun Terry Cheuk-Fung Yip

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to explore the characteristics and adverse liver outcomes of normal-weight MASLD in various populations.
Protocols followed ethical guidelines as per the Declaration of Helsinki.
Study approved by clinical research ethics committees and/or institutional review boards.
Written consent or waiver of informed consent obtained as needed.
Normal-weight MASLD shows varying characteristics in different populations.
Adverse liver outcomes were observed across diverse groups.

Implication

Clinical research reveals adverse liver outcomes in normal-weight MASLD across populations, indicating potential health risks.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Song et al. (2025) studied this question.

synapsesocial.com/papers/694018f82d562116f28f5f52 https://doi.org/10.3350/cmh.2025.0851

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Disparities among ethnic groups in mortality and outcomes among adults with <scp>MASLD</scp>: A multicenter study2024 · 25 citations
2Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts2025 · 44 citations
3Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction–Associated Steatotic Liver DiseaseObservational Study · 2026
483-OR: Metabolic Dysfunction–Associated Steatotic Liver Disease and Nonalcoholic Fatty Liver Disease Have Similar Clinical Profiles and Mortality2024 · 2 citations
5Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort StudyCohort Study · 2026 · 7 citations

More related papers

MASLD vs. MAFLD. A narrative review2025
LEAN MASLD: METABOLIC HETEROGENEITY AND IMPLICATIONS FOR DISEASE PROGRESSION2026
Beyond BMI: revealing metabolic risk in lean MASLD2025

More from Clinical and Molecular Hepatology

Epigenetic and Epitranscriptomic Regulation of Immune Checkpoint Response in Hepatocellular Carcinoma: Mechanisms, Therapeutic Targeting, and Translational ChallengesWed,
Immunotherapy and targeted therapy plus hepatic arterial infusion chemotherapy for HCC with portal vein tumor thrombosis (CHANCE2504): a nationwide target trial emulation studyWed,